CareDx, Inc.(CDNA)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
CareDx, Inc. (CDNA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CDNA at 67.5/100 on a 32-signal composite quality model, placing it at rank #362 of 2,960 stocks — the top 25% of the AI-ranked universe. CDNA scores in the top quartile across balance sheet strength (97.1), profitability (87.8), revenue growth (83.1). Areas of concern include revenue scale (35.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), CareDx, Inc. reports quarterly revenue of $131.9M, net income of $110.6M, free cash flow of $28.7M. Top institutional holders of CDNA by reported 13-F value include BlackRock, STATE STREET, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CDNA trades on the Nasdaq exchange and files with the SEC under CIK 1217234. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CDNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for CareDx, Inc. directly from SEC EDGAR.
AI Quality Score
67.5/100
AI Rank
#362
Revenue
$131.9M
Net Income
$110.6M
Free Cash Flow
$28.7M
CDNA key financials by period
CareDx, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$379.8M
$-21.4M
-8.1%
FY 2024
10-K
$333.8M
$52.5M
12.2%
FY 2023
10-K
$280.3M
$-190.3M
-72.5%
FY 2022
10-K
$321.8M
$-76.6M
-24.0%
FY 2021
10-K
$296.4M
$-30.7M
-10.0%
FY 2020
10-K
$192.2M
$-18.7M
-11.7%
Institutions holding CDNA
Institutional investors reporting a position in CareDx, Inc. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-07-30 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Revenue grew 52% YoY to $131.9M and CareDx swung to $110.6M net income, driven largely by a $113.0M one-time gain on the June 30 sale of its lab products business rather than core operating leverage.
Biggest Revenue Drivers
Testing services revenue$99.9M+61% YoY
Driven by 17% testing volume growth and $18.0M of increased net collections for tests performed in prior periods, partly offset by a $2.4M increase in the refunds reserve to payers
Patient and digital solutions revenue$19.2M+50% YoY
Higher pharmacy sales and growth in digital solutions, particularly an expanded customer base from Ottr software
Biggest Revenue Drivers
Total revenue: $131.9M+52% YoY
Testing services revenue$99.9M+61% YoY
Driven by 17% testing volume growth and $18.0M of increased net collections for tests performed in prior periods, partly offset by a $2.4M increase in the refunds reserve to payers
Patient and digital solutions revenue$19.2M+50% YoY
Higher pharmacy sales and growth in digital solutions, particularly an expanded customer base from Ottr software
Product revenue$12.8M+8% YoY
Higher sales of commercial NGS-based kitted solutions
Largest Expense Items
General and administrative$40.9M+48% YoY
Increases of $5.6M personnel-related costs, $5.6M legal and consulting expenses, and $2.3M stock-based compensation
Sales and marketing$33.4M+38% YoY
Increases of $8.7M personnel-related costs and $1.0M marketing expenses, partly offset by lower stock-based compensation
Research and development$22.4M+33% YoY
Increases of $4.0M personnel-related costs, $0.8M consulting and licensing expense, and $0.5M partnership milestone expense
Cost of patient and digital solutions$14.7M+78% YoY
Increase in cost of goods from the pharmacy business
Margins: Operating income swung to $113.2M from an $11.1M operating loss a year earlier, almost entirely due to the $113.0M gain on sale of the lab products business; underlying opex (R&D, S&M, G&A) all grew faster than revenue.
Watch Items from the Filing
Medicare represented approximately 30% of total revenue and 37% of testing services revenue in Q2 2026 (down from 34% and roughly 41% a year earlier), leaving CareDx exposed to reimbursement policy changes.
Net income of $110.6M was driven almost entirely by a $113.0M non-recurring gain on the June 30, 2026 sale of the lab products business to Eurobio for ~$171.7M; underlying operations remained near breakeven.
Testing services revenue included $18.0M (of $99.9M) from net collections on tests performed in prior periods, a favorable but not necessarily recurring contributor to reported quarterly growth.
It is reasonably possible CareDx could face a loss of up to $96.3 million plus interest in the Natera patent litigation if Natera prevails on its pending appeal, though the Company currently views the loss as not probable.
Subsequent to quarter-end, CareDx completed the $161.8M cash acquisition of Naveris (plus up to $100.0M in revenue-based earnouts through FY2027), expanding into specialty oncology testing, a market where the Company has limited operating experience.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
